Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MoonLake

Wolfspeed, Tilray, Robinhood, Etsy, And Moonlake Immunotherapeutics: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The SP 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to 46,316.07.

Benzinga

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.

Benzinga

MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment

MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its highly anticipated skin disease drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."

Investors Business Daily

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

Investors Business Daily

Why Former Highflier MoonLake Plummeted 29% After A Recent Run

MoonLake Immunotherapeutics reported mixed test results for its psoriatic arthritis treatment on Monday, and top-rated MLTX stock crashed.

Investors Business Daily

Why Top-Notch MoonLake Surged 11% And Almost Broke Out

MoonLake beat Wall Street's expectations in an update for its skin-disease treatment. MLTX stock surged near a buy point.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

These 7 Stocks Are Outperforming Nvidia In 2023

Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 996%, leading seven huge winners this year.

Investors Business Daily

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10%

MoonLake shares rocketed Tuesday after rival Acelyrin reported a failure for its skin disease treatment. MLTX stock neared a record.

Investors Business Daily

Why Mutual Fund Darling And Top 1% Stock MoonLake Just Catapulted To A Record

Biotech stock MoonLake skyrocketed Monday after the company says it set a new bar in treating a painful skin condition.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.